Daidzein from Dietary Supplement to a Drug Candidate: An Evaluation of Potential

  • ACS Omega. 2023 Aug 27;8(36):32271-32293. doi: 10.1021/acsomega.3c03741.
Mohammed Ubaid  1 ,  Salauddin  1 ,  Md Andalib Shadani  1 ,  S M Kawish  1 ,  Mohammed Albratty  2 ,  Hafiz A Makeen  3 ,  Hassan A Alhazmi  2  4  5 ,  Asim Najmi  2 ,  Khalid Zoghebi  2 ,  Maryam A Halawi  6  7 ,  Abuzer Ali  8 ,  Md Shamsher Alam  2 ,  Zeenat Iqbal  9 ,  Mohd Aamir Mirza  9
Affiliations
  • 1. School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
  • 2. Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
  • 3. Pharmacy Practice Research Unit, Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
  • 4. Substance Abuse and Toxicology Research Center, Jazan University, Jazan 45142, Saudi Arabia.
  • 5. Medical Research Center, Jazan University, Jazan 45142, Saudi Arabia.
  • 6. Pharmacy Practice, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
  • 7. Department of Haematology, Division of Cancer & Genetics School of Medicine, Cardiff University, Cardiff, Wales CF14 4XN, U.K.
  • 8. Department of Pharmacognosy, College of Pharmacy, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.
  • 9. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
PMID: 37780202 DOI: 10.1021/acsomega.3c03741
Abstract

Daidzein (DDZ) is a well-known nutraceutical supplement belonging to the class of Isoflavones. It is isolated from various sources such as alfalfa, soybean, and red clover. It demonstrates a broad array of pharmacological/beneficial properties such as cardiovascular exercise, Cholesterol reduction, and Anticancer, antifibrotic, and antidiabetic effects, which make it effective in treating a wide range of diseases. Its structure and operation are the same as those of human estrogens, which are important in preventing osteoporosis, Cancer, and postmenopausal diseases. It is thus a promising candidate for development as a phytopharmaceutical. Addressing safety, efficacy, and physicochemical properties are the primary prerequisites. DDZ is already ingested every day in varying amounts, so there should not be a significant safety risk; however, each indication requires a different dose to be determined. Some clinical trials are already being conducted globally to confirm its safety, efficacy, and therapeutic potential. Furthermore, as a result of its therapeutic influence on health, in order to establish intellectual property, patents are utilized. In light of the vast potential of eugenol, this review presents a detailed data collection on DDZ to substantiate the claim to develop it in the therapeutic category.

Products